The targeted delivery addresses local ocular manifestations by reducing inflammation and fibrosis and impacts systemic pathways, such as STAT3 signaling, offering a comprehensive strategy for managing TAO. This evidence concerns the gene STAT3 and thromboangiitis obliterans.